EA033544B1 - Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret) - Google Patents

Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)

Info

Publication number
EA033544B1
EA033544B1 EA201790546A EA201790546A EA033544B1 EA 033544 B1 EA033544 B1 EA 033544B1 EA 201790546 A EA201790546 A EA 201790546A EA 201790546 A EA201790546 A EA 201790546A EA 033544 B1 EA033544 B1 EA 033544B1
Authority
EA
Eurasian Patent Office
Prior art keywords
ret
during transfection
rearranged during
kinase inhibitors
pyridone derivatives
Prior art date
Application number
EA201790546A
Other languages
English (en)
Other versions
EA201790546A1 (ru
Inventor
Michael P Demartino
Huiping Amy Guan
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of EA201790546A1 publication Critical patent/EA201790546A1/ru
Publication of EA033544B1 publication Critical patent/EA033544B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Изобретение относится к новому соединению формулы (I) и его фармацевтически приемлемой соли, которые являются ингибиторами киназы, реаранжированной во время трансфекции (RET), к фармацевтическим композициям, их содержащим, к способам их получения и к их применению в получении лекарственного средства для лечения заболевания, опосредованного киназой, реаранжированной во время трансфекции (RET)
EA201790546A 2014-09-10 2015-09-09 Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret) EA033544B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014086197 2014-09-10
CN2015086995 2015-08-14
PCT/IB2015/056905 WO2016038552A1 (en) 2014-09-10 2015-09-09 Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201790546A1 EA201790546A1 (ru) 2017-07-31
EA033544B1 true EA033544B1 (ru) 2019-10-31

Family

ID=54186249

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790546A EA033544B1 (ru) 2014-09-10 2015-09-09 Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)

Country Status (35)

Country Link
US (4) US9918974B2 (ru)
EP (2) EP3191450B1 (ru)
JP (2) JP6538154B2 (ru)
KR (1) KR20170045350A (ru)
CN (1) CN107074768B (ru)
AU (1) AU2015313841B2 (ru)
BR (1) BR112017004900A2 (ru)
CA (1) CA2960768A1 (ru)
CL (1) CL2017000588A1 (ru)
CO (1) CO2017002273A2 (ru)
CR (1) CR20170093A (ru)
CY (1) CY1121661T1 (ru)
DK (1) DK3191450T3 (ru)
DO (1) DOP2017000059A (ru)
EA (1) EA033544B1 (ru)
ES (2) ES2816453T3 (ru)
HR (1) HRP20190815T1 (ru)
HU (1) HUE044604T2 (ru)
IL (1) IL250908B (ru)
LT (1) LT3191450T (ru)
MA (1) MA40581A (ru)
ME (1) ME03432B (ru)
MX (1) MX2017003114A (ru)
MY (1) MY181913A (ru)
PE (1) PE20170705A1 (ru)
PH (1) PH12017500425A1 (ru)
PL (1) PL3191450T3 (ru)
PT (1) PT3191450T (ru)
RS (1) RS58813B1 (ru)
SG (1) SG11201701694QA (ru)
SI (1) SI3191450T1 (ru)
TW (1) TWI683807B (ru)
UA (1) UA122213C2 (ru)
UY (1) UY36293A (ru)
WO (1) WO2016038552A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3205654T3 (pl) 2010-05-20 2019-08-30 Array Biopharma, Inc. Związki makrocykliczne jako inhibitory kinazy TRK
PE20170677A1 (es) 2014-09-10 2017-05-13 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
DK3191450T3 (da) 2014-09-10 2019-05-20 Glaxosmithkline Ip Dev Ltd Pyridonderivater som kinasehæmmere omarrangeret under transfektion (ret)
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
KR20180041135A (ko) 2015-07-16 2018-04-23 어레이 바이오파마 인크. Ret 키나아제 억제제로서 치환된 피라졸로[1,5-a]피리딘 화합물
SG11201803653QA (en) 2015-11-02 2018-05-30 Blueprint Medicines Corp Inhibitors of ret
UY37155A (es) 2016-03-17 2017-10-31 Blueprint Medicines Corp Inhibidores de ret
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US20210290620A1 (en) 2017-05-15 2021-09-23 Blueprint Medicines Corporation Combinations of RET Inhibitors and mTORC1 Inhibitors and Uses Thereof for the Treatment of Cancer Mediated by Aberrant RET Activity
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
JP7061195B2 (ja) 2018-01-18 2022-04-27 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［３，４－ｄ］ピリミジン化合物
CA3087354C (en) 2018-01-18 2023-01-03 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
RS65127B1 (sr) 2018-04-03 2024-02-29 Blueprint Medicines Corp Ret inhibitor za primenu u lečenju kancera koji ima ret alteraciju
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
TWI786742B (zh) * 2020-07-23 2022-12-11 大陸商深圳晶泰科技有限公司 吡啶酮類化合物及其製備方法和應用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008046802A1 (en) * 2006-10-16 2008-04-24 Novartis Ag Phenylacetamides useful as protein kinase inhibitors
WO2014141187A1 (en) * 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property Development Limited Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
MXPA00006233A (es) 1997-12-22 2002-09-18 Bayer Ag Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas.
ID26620A (id) 1997-12-22 2001-01-25 Bayer Ag Penghambatan kinase raf yang menggunakan urea-urea heterosiklik yang disubstitusi
US20120046290A1 (en) 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
AU4971400A (en) 1999-08-12 2001-03-13 Pharmacia & Upjohn Company 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
NZ525892A (en) * 2000-11-27 2004-11-26 Pharmacia Italia S Phenylacetamido- pyrazole derivatives their use as antitumor agents and preparation process thereof
DE10201764A1 (de) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituierte 4-Aminopyridin-Derivate
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
WO2004024694A1 (ja) 2002-09-10 2004-03-25 Kyorin Pharmaceutical Co., Ltd. ４-置換アリール-５-ヒドロキシイソキノリノン誘導体
BRPI0413757A (pt) 2003-08-22 2006-10-31 Boehringer Ingelheim Pharma métodos para o tratamento de copd e da hipertensão pulmonar
TW200530236A (en) * 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
CN103274961B (zh) * 2004-12-28 2016-05-18 阿西纳斯公司 治疗细胞增殖紊乱的化合物和方法
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
GB0507575D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US8247556B2 (en) * 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
TW200804349A (en) * 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
WO2008002676A2 (en) 2006-06-29 2008-01-03 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
WO2008033562A2 (en) * 2006-09-15 2008-03-20 Xcovery, Inc. Kinase inhibitor compounds
SI2848610T1 (en) * 2006-11-15 2018-02-28 Ym Biosciences Australia Pty Ltd Inhibitors of kinase activity
KR20120059558A (ko) 2009-08-19 2012-06-08 암비트 바이오사이언시즈 코포레이션 바이아릴 화합물 및 이의 사용 방법
WO2012082817A1 (en) 2010-12-16 2012-06-21 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
AR095308A1 (es) 2013-03-15 2015-10-07 Glaxosmithkline Ip Dev Ltd Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento
PE20170677A1 (es) 2014-09-10 2017-05-13 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
DK3191450T3 (da) * 2014-09-10 2019-05-20 Glaxosmithkline Ip Dev Ltd Pyridonderivater som kinasehæmmere omarrangeret under transfektion (ret)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008046802A1 (en) * 2006-10-16 2008-04-24 Novartis Ag Phenylacetamides useful as protein kinase inhibitors
WO2014141187A1 (en) * 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property Development Limited Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors

Also Published As

Publication number Publication date
IL250908A0 (en) 2017-04-30
AU2015313841A1 (en) 2017-03-23
BR112017004900A2 (pt) 2017-12-12
AU2015313841B2 (en) 2018-03-08
SG11201701694QA (en) 2017-04-27
CA2960768A1 (en) 2016-03-17
EP3517526A1 (en) 2019-07-31
JP6538154B2 (ja) 2019-07-03
US20190247382A1 (en) 2019-08-15
TWI683807B (zh) 2020-02-01
CR20170093A (es) 2017-07-17
HUE044604T2 (hu) 2019-11-28
JP2017527578A (ja) 2017-09-21
US20190022078A1 (en) 2019-01-24
ME03432B (me) 2020-01-20
JP2019163316A (ja) 2019-09-26
ES2725704T3 (es) 2019-09-26
DOP2017000059A (es) 2017-03-31
CN107074768B (zh) 2019-12-10
UA122213C2 (uk) 2020-10-12
CL2017000588A1 (es) 2017-10-06
CN107074768A (zh) 2017-08-18
RS58813B1 (sr) 2019-07-31
EP3517526B1 (en) 2020-08-19
MA40581A (fr) 2019-04-10
US20180147194A1 (en) 2018-05-31
PH12017500425B1 (en) 2017-07-31
MY181913A (en) 2021-01-14
LT3191450T (lt) 2019-06-10
PT3191450T (pt) 2019-05-29
CY1121661T1 (el) 2020-07-31
US20170340617A1 (en) 2017-11-30
PH12017500425A1 (en) 2017-07-31
WO2016038552A1 (en) 2016-03-17
DK3191450T3 (da) 2019-05-20
CO2017002273A2 (es) 2017-06-20
HRP20190815T1 (hr) 2019-07-12
US10111866B2 (en) 2018-10-30
KR20170045350A (ko) 2017-04-26
IL250908B (en) 2020-11-30
EP3191450A1 (en) 2017-07-19
EA201790546A1 (ru) 2017-07-31
PE20170705A1 (es) 2017-05-21
UY36293A (es) 2016-04-01
ES2816453T3 (es) 2021-04-05
EP3191450B1 (en) 2019-04-10
US10709695B2 (en) 2020-07-14
PL3191450T3 (pl) 2019-08-30
TW201625534A (en) 2016-07-16
MX2017003114A (es) 2017-11-15
JP6728447B2 (ja) 2020-07-22
US9918974B2 (en) 2018-03-20
US10292975B2 (en) 2019-05-21
SI3191450T1 (sl) 2019-07-31

Similar Documents

Publication Publication Date Title
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
MX2017010477A (es) Compuestos triciclicos y usos de los mismos en medicina.
EA033266B1 (ru) Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
MD4800B1 (ru) Соединения аминопиримидинила в качестве ингибиторов JAK
EA202090486A3 (ru) Соединения для лечения спинальной мышечной атрофии
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
MY197698A (en) Oxysterols and methods of use thereof
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
PH12016501462A1 (en) Neprilysin inhibitors
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
TW201613864A (en) Novel compounds
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
TW201613909A (en) Benzoxazinone amides as mineralocorticoid receptor modulators
PH12017500089A1 (en) Aldosterone synthase inhibitors
MX355072B (es) Derivados de riperidina 3-espirociclicos como antagonistas de los receptores de grelina.
MX369025B (es) Inhibidores de aldosterona sintasa.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
MX2017002627A (es) Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ RU